Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary
G

Glycopyrronium + Indacaterol + Mometasone

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

No

Subsidy Information and Financing Scheme

No

Active ingredients: Glycopyrronium | Indacaterol | Mometasone

General information

Subsidy Information and Financing Scheme

Not Applicable

Drug Guidance for Subsidy

17/02/2025 Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) and 200/62.5/25 mcg (30 inhalations) inhalation powder for treating asthma; and

  • Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) inhalation powder for treating chronic obstructive pulmonary disease.

Funding status

[R] Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) and 200/62.5/25 mcg (30 inhalations) inhalation powder are recommended for inclusion on the Standard Drug List (SDL) for the abovementioned indications from 1 April 2025.

[NR] SDL subsidy does not apply to any formulations or strengths of beclomethasone dipropionate/glycopyrronium/formoterol, budesonide/glycopyrronium/formoterol, mometasone furoate/glycopyrronium/indacaterol, or tiotropium.

View legend

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch.

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information.

Respiratory (inhalation)

* Clinical information is available for this product.

Back to top